Workstream 3 focuses on rare uro-recto-genital tumours. The Expertise Areas (EAs) covered by Workstream 3 are: A key part of EU health strategy is Europe’s Beating Cancer Plan, enhancing the cancer journey from prevention to survivorship. Network-generated literature underscores the effectiveness of a centralised approach for penile, testicular, adrenal, and soft tissue cancers. Specialised surgical training will increase organ preservation rates and decrease cancer mortality. Tahlita Zuiverloon is a physician-scientist and urologist at the Department of Urology, Erasmus MC Cancer Institute Rotterdam, The Netherlands. She is the head of the oncological urology subdivision and the medical coordinator of the urology outpatient clinic. She specialises in complex retroperitoneal surgery, focusing specifically on renal, testicular, and upper tract urothelial cancer. She received her medical degree and MSc in biomedical sciences from Leiden University. She worked as a voluntary medic in Malawi, Africa, for a year. After this, she started her PhD at Erasmus MC and defended her thesis, “Molecular diagnosis in bladder cancer”, in 2013. From 2011 to 1016, she completed her residency in urology and worked as a postdoctoral research fellow at the University of Colorado from 2017 to 2019. Afterwards, she was a clinical fellow at the University Hospital of Dusseldorf, Germany and became an assistant professor. Dr Zuiverloon is currently a faculty member at Erasmus MC’s Department of Urology, and she founded the Erasmus MC Center for Complex Retroperitoneal Surgery, which she has led to becoming an (inter)national certified expert centre for testicular and upper tract urothelial cancer. She runs a research group with a focus on urothelial and testicular cancer. Her vision for the coming years is to expand the EU network for Workstream 3, stimulate international exchange programmes for specialised surgical training, set up working groups to promote centralisation of care with a focus on survivorship, and to extend and expand prospective data collection for each expertise area, which will be the base for funding applications.
Workstream 3: Rare uro-recto-genital tumours
Leads
WS Lead: Tahlita Zuiverloon
Clinical Lead: Peter-Paul M. Willemse
Dr. Peter-Paul M. Willemse is an oncological urologist at the University Medical Center Utrecht, where he is Head of the oncological urology board. His primary research focus is the diagnosis and treatment of urological malignancies. He is a member of the working group on Quality Assessment and the working group on Oncological Urology of the Dutch Urologic Association.Education Lead: Mariangela Mancini
Research Lead: Vacant
Workstream 3
